KineMed renews non-exclusive research agreement with Pfizer

The research collaboration will use KineMed’s dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

KineMed R&D executive vice-president Dr. Scott Turner said that the powerful discovery and investigative abilities of novel disease pathways are key strengths of the company’s translational platform.

"We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials," Turner added.

According to the World Health Organization, Diabetes is an emerging global healthcare epidemic with an estimated 347 million people affected.